MétaCan
Menu
← Back to cohort
Record W2115445516 · doi:10.1200/jco.2005.03.9644

Radiotherapy and Hodgkin's Lymphoma

2005· letter· en· W2115445516 on OpenAlexaboutno aff
Prajnan Das, Chul S. Ha, James D. Cox

Bibliographic record

VenueJournal of Clinical Oncology · 2005
Typeletter
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsnot available
FundersNational Cancer Institute
KeywordsMedicineRadiation therapyHodgkin lymphomaLymphomaOncologyInternal medicine

Abstract

fetched live from OpenAlex

issue of the Journal of Clinical Oncology regarding the National Cancer Institute of Canada (NCI-C) trial.1,2 In this trial, patients with stage I to IIA Hodgkin's lymphoma were randomly assigned to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone or subtotal nodal radiation.Patients with unfavorable risk disease in the radiotherapy arm also received ABVD.While there was no difference in overall or event-free survival between the two arms, freedom from disease progression was significantly higher in the radiotherapy arm, compared to the chemotherapy alone arm (93% v 87%, P ϭ .006).The NCI-C trial has been the only trial designed to compare survival in adult patients treated with ABVD alone and those treated with radiotherapy, with or without ABVD.However, other recent studies have also investigated the role of radiotherapy in early-stage Hodgkin's lymphoma.As noted in the editorial, a randomized trial from India showed that in patients achieving a complete remission after 6 cycles of ABVD, the addition of radiotherapy significantly improved the 8-year event-free survival (88% v 76%, P ϭ .01)and overall survival (100% v 89%, P ϭ .002). 3 The findings of this trial may not necessarily be applicable to all early-stage Hodgkin's lymphoma patients, since a large number of patients in this trial were under age 15, had stage III-IV lymphoma, or had mixed cellularity histology.The results from the recently presented European Organisation for Research and Treatment of Cancer GELA H9-F trial may be more pertinent.4 In the H9-F trial, patients with favorable, early stage Hodgkin's lymphoma with a complete remission after six cycles of epirubicin, bleomycin, vinblastine, and prednisone were randomly assigned to one of three arms: no radiotherapy, 20 Gy involved field, or 36 Gy involved field radiotherapy.The no radiotherapy arm of the trial had to be closed early since predefined stopping rules were met.The 4-year event-free survival was significantly lower in the no-radiotherapy arm (70%), compared to the 20 Gy (84%) and 36 Gy (87%) arms (P Ͻ .001).Of note, the epirubicin, bleomycin, vinblastine, and prednisone regimen in this trial may be associated with a higher rate of relapse than ABVD.A randomized trial from Memorial Sloan-Kettering Cancer Center failed to find any significant difference in overall survival or freedom from progression in patients treated with ABVD alone or ABVD followed

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.031
Threshold uncertainty score0.061

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0070.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.101
GPT teacher head0.454
Teacher spread0.353 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicLymphoma Diagnosis and Treatment→French-language works237,207→